Merely inhibiting RORγt may not adequately resolve the complete pathology of specific diseases; in certain circumstances, such as inflammatory bowel disease, extensive IL-17 suppression has demonstrated diminished efficacy or even adverse effects. The gene discussed is IL17A; the disease is inflammatory bowel disease.